DE60224275T2 - Moleküle und verfahren zur inhibierung der freisetzung von kim-1 - Google Patents

Moleküle und verfahren zur inhibierung der freisetzung von kim-1 Download PDF

Info

Publication number
DE60224275T2
DE60224275T2 DE60224275T DE60224275T DE60224275T2 DE 60224275 T2 DE60224275 T2 DE 60224275T2 DE 60224275 T DE60224275 T DE 60224275T DE 60224275 T DE60224275 T DE 60224275T DE 60224275 T2 DE60224275 T2 DE 60224275T2
Authority
DE
Germany
Prior art keywords
antibody
kim
antigen
binding fragment
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60224275T
Other languages
German (de)
English (en)
Other versions
DE60224275D1 (de
Inventor
Veronique Boxborough BAILLY
Joseph Wayland BONVENTRE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Biogen Inc
Biogen MA Inc
Original Assignee
General Hospital Corp
Biogen Idec Inc
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp, Biogen Idec Inc, Biogen Idec MA Inc filed Critical General Hospital Corp
Publication of DE60224275D1 publication Critical patent/DE60224275D1/de
Application granted granted Critical
Publication of DE60224275T2 publication Critical patent/DE60224275T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60224275T 2001-06-01 2002-05-31 Moleküle und verfahren zur inhibierung der freisetzung von kim-1 Expired - Lifetime DE60224275T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29544901P 2001-06-01 2001-06-01
US295449P 2001-06-01
US29590701P 2001-06-04 2001-06-04
US295907P 2001-06-04
PCT/US2002/017402 WO2002098920A1 (en) 2001-06-01 2002-05-31 Molecules and methods for inhibiting shedding of kim-1

Publications (2)

Publication Number Publication Date
DE60224275D1 DE60224275D1 (de) 2008-02-07
DE60224275T2 true DE60224275T2 (de) 2008-12-11

Family

ID=26969139

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60224275T Expired - Lifetime DE60224275T2 (de) 2001-06-01 2002-05-31 Moleküle und verfahren zur inhibierung der freisetzung von kim-1

Country Status (10)

Country Link
US (3) US7041290B2 (OSRAM)
EP (1) EP1401869B1 (OSRAM)
JP (2) JP4527394B2 (OSRAM)
AT (1) ATE382060T1 (OSRAM)
AU (1) AU2002305785B2 (OSRAM)
CA (1) CA2448427C (OSRAM)
DE (1) DE60224275T2 (OSRAM)
DK (1) DK1401869T3 (OSRAM)
NZ (1) NZ530457A (OSRAM)
WO (1) WO2002098920A1 (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997044460A1 (en) * 1996-05-24 1997-11-27 Biogen, Inc. Modulators of tissue regeneration
WO2001098481A2 (en) * 2000-06-16 2001-12-27 Biogen, Inc. Renal regulatory elements and methods of use thereof
AU2002305785B2 (en) * 2001-06-01 2008-01-17 Biogen Ma Inc. Molecules and methods for inhibiting shedding of KIM-1
EP1576169B1 (en) * 2002-03-19 2016-08-10 Celldex Therapeutics, Inc. Therapeutic polypeptides and methods of use
AU2013205381B2 (en) * 2002-03-19 2016-04-14 Celldex Therapeutics, Inc. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
PT1585546E (pt) * 2002-12-30 2008-11-14 Biogen Idec Inc Antagonistas de kim-1 e sua utilização para modular o sistema imunitário
JP2007525434A (ja) * 2003-03-19 2007-09-06 アブジェニックス インコーポレイテッド Ｔ細胞、免疫グロブリンドメインおよびムチンドメイン１（ｔｉｍ−１）抗原に対する抗体およびその使用。
AU2013242840B2 (en) * 2003-03-19 2017-01-19 Amgen Fremont Inc. Antibodies Against T Cell Immunoglobulin Domain and Mucin Domain 1 (TIM-1) Antigen and Uses Thereof
EP1532984A1 (en) * 2003-11-19 2005-05-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti CD44 antibodies for eradicating stem cells in acute myeloid leukemia
EP1865985B1 (en) 2005-03-02 2010-08-25 Biogen Idec MA Inc. Kim-1 antibodies for treatment of th2-mediated conditions
CA2629453C (en) 2005-11-10 2018-03-06 Curagen Corporation Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
RS64039B1 (sr) 2008-11-10 2023-04-28 Alexion Pharma Inc Metode i kompozicije za lečenje poremećaja povezanih sa komplementom
CN102713632B (zh) 2009-12-23 2015-10-07 希尔氏宠物营养品公司 用于诊断和治疗犬肾脏病症的组合物和方法
EP2523976B1 (en) 2010-01-11 2018-04-25 Alexion Pharmaceuticals, Inc. Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
KR101800913B1 (ko) 2010-04-30 2017-12-20 알렉시온 파마슈티칼스, 인코포레이티드 항-c5a 항체들과 이 항체들을 이용하는 방법
JP6150734B2 (ja) 2011-02-03 2017-06-21 アレクシオン ファーマシューティカルズ， インコーポレイテッド 同種移植片の生存を長期化するための抗ｃｄ２００抗体の使用
WO2013078089A1 (en) * 2011-11-22 2013-05-30 Biogen Idec Ma Inc. Anti-tim-1 antibodies and uses thereof
WO2015023836A1 (en) * 2013-08-16 2015-02-19 The Brigham And Women's Hospital, Inc. Kim-1 as a therapeutic target in conditions associated with kidney fibrosis
US10712349B2 (en) 2014-04-15 2020-07-14 The Brigham And Women's Hospital, Inc. Circulating KIM-1 levels for detection of pathologies associated with injury to, or cancer of, the kidney
WO2018132695A1 (en) 2017-01-13 2018-07-19 Celdara Medical, Llc Chimeric antigen receptors targeting tim-1
US11820728B2 (en) 2017-04-28 2023-11-21 Acuitas Therapeutics, Inc. Carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
EP3852911B1 (en) 2018-09-21 2025-01-22 Acuitas Therapeutics, Inc. Systems and methods for manufacturing lipid nanoparticles and liposomes
US11453639B2 (en) 2019-01-11 2022-09-27 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
MX2023000614A (es) 2020-07-16 2023-02-13 Acuitas Therapeutics Inc Lipidos cationicos para usarse en nanoparticulas lipidicas.
IL313486A (en) 2021-12-16 2024-08-01 Acuitas Therapeutics Inc Lipids for use in lipid nanoparticle formulations

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622861A (en) 1994-08-05 1997-04-22 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA encoding hepatitis A virus receptor
WO1997044460A1 (en) * 1996-05-24 1997-11-27 Biogen, Inc. Modulators of tissue regeneration
WO2001098481A2 (en) * 2000-06-16 2001-12-27 Biogen, Inc. Renal regulatory elements and methods of use thereof
AU2002305785B2 (en) * 2001-06-01 2008-01-17 Biogen Ma Inc. Molecules and methods for inhibiting shedding of KIM-1
EP1406653A4 (en) 2001-06-29 2005-05-04 Univ Leland Stanford Junior T CELL REGULATION GENES AND METHOD OF USE THEREOF
US7838220B2 (en) 2001-06-29 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University T cell regulatory genes associated with immune disease
EP1434881A4 (en) 2001-09-17 2005-10-26 Protein Design Labs Inc METHOD FOR DIAGNOSIS OF CANCER COMPOSITIONS AND METHOD FOR SCREENING ON CANCER MODULATORS
WO2003042661A2 (en) 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US7687454B2 (en) 2001-12-03 2010-03-30 The University Of British Columbia Effectors of innate immunity determination
AU2003303082B2 (en) 2002-01-30 2009-07-02 Dana-Farber Cancer Institute, Inc. Compositions and methods related to TIM-3, a Th1-specific cell surface molecule
EP1576169B1 (en) 2002-03-19 2016-08-10 Celldex Therapeutics, Inc. Therapeutic polypeptides and methods of use
GB0215509D0 (en) 2002-07-04 2002-08-14 Novartis Ag Marker genes
JP2007525434A (ja) 2003-03-19 2007-09-06 アブジェニックス インコーポレイテッド Ｔ細胞、免疫グロブリンドメインおよびムチンドメイン１（ｔｉｍ−１）抗原に対する抗体およびその使用。
WO2005001092A2 (en) 2003-05-20 2005-01-06 Wyeth Compositions and methods for diagnosing and treating cancers

Also Published As

Publication number Publication date
DE60224275D1 (de) 2008-02-07
US20050112117A1 (en) 2005-05-26
US7041290B2 (en) 2006-05-09
US7696321B2 (en) 2010-04-13
US20080124336A1 (en) 2008-05-29
US20060153836A1 (en) 2006-07-13
EP1401869A1 (en) 2004-03-31
EP1401869B1 (en) 2007-12-26
ATE382060T1 (de) 2008-01-15
WO2002098920A1 (en) 2002-12-12
CA2448427A1 (en) 2002-12-12
US7300652B2 (en) 2007-11-27
JP2005505256A (ja) 2005-02-24
NZ530457A (en) 2007-12-21
JP4527394B2 (ja) 2010-08-18
CA2448427C (en) 2013-09-24
JP2010150291A (ja) 2010-07-08
EP1401869A4 (en) 2005-10-19
AU2002305785B2 (en) 2008-01-17
DK1401869T3 (da) 2008-04-28

Similar Documents

Publication Publication Date Title
DE60224275T2 (de) Moleküle und verfahren zur inhibierung der freisetzung von kim-1
DE60226036T3 (de) ANTIKÖRPER, DER DAS GM1-GANGLIOSID-GEBUNDENE AMYLOID-b-PROTEIN ERKENNT, UND DNA, DIE FÜR DIESEN ANTIKÖRPER CODIERT
DE60130797T2 (de) Verwendung von spezifischen erbb4 antagonisten zur behandlung von stenose
DE69434908T2 (de) Rezeptor an der oberfläche von aktivierten t-zellen:act4
DE69833014T2 (de) Menschliche toll homologen
DE69735294T2 (de) Spezifische monoklonale antikörper für die extrazelluläre domäne von protasta-spezifischem membranantigen
DE69729209T2 (de) Humanisierte anti-koerper gegen cd11a
EP1805221B1 (de) Monoklonaler antikörper gegen humanen frizzled-4-rezeptor
AU2002305785A1 (en) Molecules and methods for inhibiting shedding of KIM-1
DE69333039T2 (de) Monoklonaler antikörper gegen ein humanes mdr1-gen produkt, das eine resistenz gegen verschiedene medikamente erzeugt und seine verwendung
EP1928905B1 (de) Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
DE69714451T2 (de) Prionbindende proteine und deren verwendungen
DE69435083T2 (de) Antikörper gegen den IL-8 Rezeptor und deren therapeutische Verwendungen
DE69832539T2 (de) Polypeptid und dafür kodierendes Nukeinsäure
DE69526542T2 (de) uPA-Bindungstelle auf 2+3 Domäne von uPAR und damit reagierende Antikörper
DE19617940A1 (de) Nebenhoden-spezifisches Rezeptorprotein und dessen Verwendung
DE69626510T2 (de) Verwendung des leukämie-inhibitor-faktor und endothelin antagonisten
DE69932342T2 (de) Verfahren und zusammensetzungen zur hemmung von neoplastischem zellwachstums
DE69813181T2 (de) Icam-4 und dessen diagnostische verwendungen
DE69932644T2 (de) Menschliches Protein mit in vitro antiproliferativer Aktivität.
DE69931363T2 (de) Sp22, ein mit fruchtbarkeit assoziiertes protein aus spermien, und ein verfahren zum abschätzen und beeinflussen der männlichen fruchtbarkeit durch dessen gebrauch
DE3686277T2 (de) Verfahren zur auslese von hybridomen, die spezifische antikoerper gegen unzugaengliche zelloberflaecheantigene erzeugen.
DE69829417T2 (de) Polypeptide und dafür kodierende Nukleinsäure
DE69835170T2 (de) Polypeptid und dafür kodierendes Nukleinsäure
DE20320429U1 (de) Monoklonale Antikörpertools für die biokonformatische Analyse

Legal Events

Date Code Title Description
8364 No opposition during term of opposition